



Please Fax Completed Form To: 888-340-3699
Please Send a Copy of The Patient's Insurance Cards (Front & Back)
Please Send a Copy of The Patient's Up-to-Date Clinical Notes

PATIENT INFORMATION (Complete or Fax Existing Chart)
PRESCRIBER INFORMATION
Name: \_\_\_\_\_ DOB: \_\_\_\_\_
Address: \_\_\_\_\_
City, State, Zip: \_\_\_\_\_
Phone: \_\_\_\_\_ Alt. Phone: \_\_\_\_\_
Email: \_\_\_\_\_ SS#: \_\_\_\_\_
Gender:  M  F Weight: \_\_\_\_\_ (lbs) Ht: \_\_\_\_\_
Allergies: \_\_\_\_\_
Prescriber Name: \_\_\_\_\_
State License: \_\_\_\_\_
NPI #: \_\_\_\_\_ Tax ID: \_\_\_\_\_
Address: \_\_\_\_\_
City, State, Zip: \_\_\_\_\_
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_
Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)
Primary Insurance: \_\_\_\_\_ Secondary Insurance (If Applicable): \_\_\_\_\_
Plan #: \_\_\_\_\_ Plan #: \_\_\_\_\_
Group #: \_\_\_\_\_ Group #: \_\_\_\_\_
RX Card (PBM): \_\_\_\_\_ RX Card (PBM): \_\_\_\_\_
BIN: \_\_\_\_\_ PCN: \_\_\_\_\_ BIN: \_\_\_\_\_ PCN: \_\_\_\_\_

CLINICAL INFORMATION
 J82.83 Severe Eosinophilic Asthma  L50.1 Chronic Idiopathic Urticaria  Other: \_\_\_\_\_
Prior Anaphylactic Reaction:  No  Yes (Reason/Date): \_\_\_\_\_
Lab Results:
Positive Skin or RAST test to Perennial Aeroallergen:  Yes  No Test Date: \_\_\_\_\_ - \_\_\_\_\_ - \_\_\_\_\_
Serum IgE Level \_\_\_\_\_ IU/ML Test Date: \_\_\_\_\_ - \_\_\_\_\_ - \_\_\_\_\_
Serum Eosinophil Level: \_\_\_\_\_ cells/mcL Test Date: \_\_\_\_\_ - \_\_\_\_\_ - \_\_\_\_\_
Sputum Eosinophiles \_\_\_\_\_ cells/mcL Test Date: \_\_\_\_\_ - \_\_\_\_\_ - \_\_\_\_\_

XOLAIR® ORDERS
Prescription type:  New start  Restart  Continued therapy Total Doses Received: \_\_\_\_\_ Date of Last Injection/Infusion: \_\_\_\_\_
Medication Dose/Frequency Refills
Pre-Medication Dose/Strength Directions

INFUSION REACTION ORDERS
Mild reaction protocol:
 Diphenhydramine 25mg IV, one time, for pruritus.
If symptoms worsen, see orders for moderate to severe reactions.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.



Please Fax Completed Form To: 888-340-3699

Please Send a Copy of The Patient's Insurance Cards (Front & Back)

Please Send a Copy of The Patient's Up-to-Date Clinical Notes

Moderate reaction protocol:

- Acetaminophen 650mg PO, one time, for pyrexia or rigors
Diphenhydramine 50mg IV, one time, for pruritus or urticaria
Methylprednisolone 125mg IV, one time, for respiratory or neurologic symptoms

If symptoms worsen, see interventions for severe reactions

Severe reaction protocol: (Call 911 if initiated):

- Titrate oxygen via continuous flow per nasal cannula or face mask to maintain spO2 of greater than ninety-five percent (>95%)
Diphenhydramine 50mg IV, one time, for respiratory symptoms, edema, or anaphylaxis
Methylprednisolone 125mg IV, one time, for respiratory symptoms, edema, or anaphylaxis
Sodium Chloride 0.9% 500mL IV over 30-60 min, one time, for cardiovascular symptoms
Epinephrine 0.3mg/0.3mL IM into mid-antrolateral aspect of thigh of anaphylaxis, may repeat x1 in 5-15 minutes if symptoms are not resolved or worsen

FLUSHING & LOCKING ORDERS

Flushing Protocol (>66lbs/33kg)

PIV and Midline:

- 0.9% Sodium Chloride 2-5mL IV flush before and after each infusion

Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter:

- 0.9% Sodium Chloride 5mL IV flush before infusion/lab draw and 10mL IV flush after infusion/lab draw

Locking Protocol (>66lbs/33kg)

PIV and Midline:

- Heparin Sodium 10 units/mL 1mL IV final flush post normal saline flush

PICC:

- Heparin Sodium 10 units/mL 3mL IV final flush post normal saline flush

Implanted Port, Tunneled Catheter, and Non-tunneled Catheter:

- Heparin Sodium 100 units/mL 3-5mL IV final flush post normal saline flush

\*\* May substitute Dextrose 5% in Water, or alternative, for 0.9% Sodium Chloride, when indicated due to incompatibility with medications being infused

SIGNATURE

We hereby authorize Infuse IQ LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.

X \_\_\_\_\_

Prescriber Signature

Date: \_\_\_\_\_

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.